Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Savings Top $338bn In 2020

As Savings Figure Linked To Biosimilars More Than Trebles To $7.9bn

Executive Summary

Savings achieved in the US through the use of generics and biosimilars hit a new high in 2020, reaching $338bn, according to new figures released by the AAM.

You may also be interested in...



FDA Suggests ‘Institutional Resistance’ To Levothyroxine Generics Is Misplaced

Following the publication of a real-world case-study of levothyroxine use that included switching between different versions of the product, the FDA has suggested that “institutional resistance” to generics – including from American Thyroid Association guidance that warns against switching – “may not be supported by real-world evidence.”

National Alliance Launches Laundry List Of Biosimilar Uptake Strategies

The National Alliance of Healthcare Purchaser Coalitions has worked with seven regional organizations and over 60 employers to identify five areas where US employers can take specific actions to expand access to biosimilars.

AAM Blasts Build Back Better But Bernstein Offers Balance

Biosimilars could be affected significantly by Build Back Better’s drug price negotiations provision, but industry associations and analysts differ on just how much.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

GB151265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel